Trillium Asset Management, LLC Biogen Inc. Transaction History

Trillium Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $228,253 - $289,542	-849 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$220.06 - $304.07 $130,275 - $180,009	-592 Reduced 41.08%	849 $252,000
Q3 2019 Nov 06, 2019	BUY	$217.44 - $243.88 $77,843 - $87,309	358 Added 33.06%	1,441 $336,000
Q2 2019 Aug 08, 2019	SELL	$219.29 - $241.72 $4.57 Million - $5.04 Million	-20,831 Reduced 95.06%	1,083 $253,000
Q1 2019 May 06, 2019	SELL	$216.71 - $338.96 $2.55 Million - $3.99 Million	-11,782 Reduced 34.97%	21,914 $5.18 Million
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $412,737 - $522,775	-1,482 Reduced 4.21%	33,696 $10.1 Million
Q3 2018 Nov 09, 2018	BUY	$293.51 - $383.83 $94,803 - $123,977	323 Added 0.93%	35,178 $12.4 Million
Q2 2018 Aug 01, 2018	SELL	$257.52 - $306.91 $53,821 - $64,144	-209 Reduced 0.6%	34,855 $10.1 Million
Q1 2018 May 09, 2018	BUY	$260.13 - $367.91 $129,544 - $183,219	498 Added 1.44%	35,064 $9.6 Million
Q4 2017 Feb 01, 2018	SELL	$307.64 - $344.58 $153,512 - $171,945	-499 Reduced 1.42%	34,566 $11 Million
Q3 2017 Nov 02, 2017	BUY	$281.15 - $329.69 $9.86 Million - $11.6 Million	35,065	35,065 $11 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Trillium Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Trillium Asset Management, LLC with notifications on news.